STTT：于金明院士團隊深度解析放療與免疫治療的發展前景( 四 ) _健康小知識

結語
照射多病灶的免疫調節效應、低劑量放療專屬的“遠端效應” ，以及放療激活的全身免疫應答，都讓iRT聯合治療模式頗受期待，但在iRT被臨床常規應用之前，還需要跨越一系列的難關和挑戰，相信未來的臨床研究會給出更好的答案。
已購買課程的朋友，
直接進入小程序收聽加餐哦~
參考文獻：
1.UpadhayaS,NeftelinovST,HodgeJ,etal.ChallengesandopportunitiesinthePD1/PDL1inhibitorclinicaltriallandscape[J].NatureReviewsDrugDiscovery,2022,21:482-483.
2.ZhangZ,LiuX,ChenD,etal.Radiotherapycombinedwithimmunotherapy:thedawnofcancertreatment[J].SignalTransductionandTargetedTherapy,2022,7:258.
3.PostowMA,CallahanMK,BarkerCA,etal.Immunologiccorrelatesoftheabscopaleffectinapatientwithmelanoma[J].NewEnglandJournalofMedicine,2012,366(10):925-931.
4.DemariaS,BhardwajN,McBrideWH,etal.Combiningradiotherapyandimmunotherapy:arevivedpartnership[J].InternationalJournalofRadiationOncology*Biology*Physics,2005,63(3):655-666.
5.ChangJY,MehranRJ,FengL,etal.StereotacticablativeradiotherapyforoperablestageInon-small-celllungcancer(revisedSTARS):long-termresultsofasingle-arm,prospectivetrialwithprespecifiedcomparisontosurgery[J].TheLancetOncology,2021,22(10):1448-1457.
6.BernsteinMB,KrishnanS,HodgeJW,etal.Immunotherapyandstereotacticablativeradiotherapy(ISABR):acurativeapproach?[J].NatureReviewsClinicalOncology,2016,13(8):516-524.
7.BarsoumianHB,RamapriyanR,YounesAI,etal.Low-doseradiationtreatmentenhancessystemicantitumorimmuneresponsesbyovercomingtheinhibitorystroma[J].JournalforImmunoTherapyofCancer,2020,8(2):e000537.
8.WelshJW,TangC,DeGrootP,etal.PhaseIITrialofIpilimumabwithStereotacticRadiationTherapyforMetastaticDisease:Outcomes,Toxicities,andLow-DoseRadiation–RelatedAbscopalResponsesIpilimumabandSABRforLungorLiverMetastases[J].CancerImmunologyResearch,2019,7(12):1903-1909.
9.PatelRR,HeK,BarsoumianHB,etal.High-doseirradiationincombinationwithnon-ablativelow-doseradiationtotreatmetastaticdiseaseafterprogressiononimmunotherapy:ResultsofaphaseIItrial[J].RadiotherapyandOncology,2021,162:60-67.
10.WelshJ,MenonH,ChenD,etal.Pembrolizumabwithorwithoutradiationtherapyformetastaticnon-smallcelllungcancer:arandomizedphaseI/IItrial[J].JournalforImmunoTherapyofCancer,2020,8(2):e001001.
11.JungHA,NohJM,SunJM,etal.RealworlddataofdurvalumabconsolidationafterchemoradiotherapyinstageIIInon-small-celllungcancer[J].LungCancer,2020,146:23-29.
12.ChenD,MenonH,VermaV,etal.Responseandoutcomesafteranti-CTLA4versusanti-PD1combinedwithstereotacticbodyradiationtherapyformetastaticnon-smallcelllungcancer:retrospectiveanalysisoftwosingle-institutionprospectivetrials[J].JournalforImmunoTherapyofCancer,2020,8(1):e000492.
13.YanM,DurmGA,MamdaniH,etal.Consolidationnivolumab/ipilimumabversusnivolumabfollowingconcurrentchemoradiationinpatientswithunresectablestageIIINSCLC:AplannedinterimsafetyanalysisfromtheBTCRCLUN16-081trial[J].JournalofClinicalOncology,2020,38(Suppl_15):9010.
【STTT：于金明院士團隊深度解析放療與免疫治療的發展前景】本文作者丨譚碩